Sector portfolio · Family office · Singapore
Hill House Capital's Biotech portfolio
Hill House Capital has backed 32 Biotech startups in rounds we track, $6.2B between them, shown by the stage each has reached. The best-funded is Grail.
32startups backed
4stages
$6.2Braised between them
Series Bbiggest stage
Hill House Capital's whole portfolioHill House Capital's profile
Series B
11
Funding by segment
- Series B$3.7B11
- Series C and later$1.8B10
- Stage not reported$662M6
- Series A$112M5
Where they are based
- United States14$4.2B
- China13$1.6B
- Hong Kong SAR China1$150M
- Austria1$97M
- United Kingdom1$150M
United States
China
Hong Kong SAR China
Austria
United KingdomFounded
1Earlier
212
113
114
515
316
317
18
219
220
421
22
23
24
25
26
8 without a founding year on record.
Total raised
- Under $1M0
- $1M to $10M3
- $10M to $50M8
- $50M to $250M12
- $250M to $1B8
- $1B and over1
Each dot is a startup: the year it was founded across, the total it has raised up (each line is ten times the one below). Pick a segment to pick it out.
24 of 32 startups shown; the rest have no founding year or amount on record.
- 1 to 2
- 3 to 7
- 8 to 24
- 25 to 99
- 100 and more
- United States14
- China13
- Hong Kong SAR China1
- Austria1
- United Kingdom1
Startups by country, 5 countries in all.
Segment by segment
Series B
11 startups · $3.7B raised
- GGrailUnited States$1.6B
Gossamer BioGossamer Bio is a biopharmaceutical company focused on the discovery and development of novel and differentiated therapeutic products.United States$567M- CCStoneChina$410M
- VBViela BioViela Bio is a clinical-stage biotechnology company pioneering and advancing treatments for severe inflammation and autoimmune diseases.United States$325M
Haihe BiopharmaHaihe Biopharma is a biopharmaceutical company that develops cancer anti-tumour drugs.China$317M
Neon TherapeuticsNEON Therapeutics is focused on unlocking the full potential of the immune system to recognize and attack cancer.United States$161M- TTCR2United States$125M
BluephaBluepha is a leading synthetic biology company in China, founded in 2016 by Dr.China$59M
Series C and later
10 startups · $1.8B raised
Arcus BiosciencesArcus Biosciences is a biopharmaceutical company that discovers, develops, and commercializes novel therapies for the treatment of cancer.United States$427M
Nature's FyndNature's Fynd is a Chicago-based food-tech company that specializes in creating animal-free meat and dairy alternatives.United States$350M
Abogen BiosciencesAbogen Biosciences is a clinical-stage biotechnology company focused on RNA-based medicines, particularly in mRNA science and technology.China$300M
AntengeneAntengene is a developer of biotechnology and bio-pharmaceuticals intended to provide medicine treatment for tumor.China$217M- IInnoventHong Kong SAR China$150M
HookipaHookipa GmbH – Private Equity, Finanzierungen, Start-Up Coaching und Vermittlung von Kontakten & Personal.Austria$97M
GRIT BiotechnologyGrit Biotechnology, also known as Grit Bio, is a clinical-stage biopharmaceutical company based in Shanghai, China.China$84M
Antiva BiosciencesAntiva Biosciences is a biopharmaceutical company developing therapeutics for the treatment of diseases caused by HPV infection.United States$75M
Stage not reported
6 startups · $662M raised
ArriVentArriVent develops pharmaceutical products to cure presently untreatable cancer.United States$325M
Tenpoint TherapeuticsTenpoint Therapeutics is a biotechnology company pursuing vision-restoring engineered cell-based therapeutics.United Kingdom$150M
ArvinasArvinas is a clinical-stage biotechnology company leading the way in targeted protein degradation therapeutics.United States$111M- IInnocareInnoCare is a Chinese biopharmaceutical company that develops treatment for cancer and autoimmune diseases.China$55M
Hookipa PharmaHookipa is a clinical stage biotech company developing best-in-class active immunization therapies for infectious diseases and oncology.United States$14M
Everest MedicinesEverest Medicines is dedicated to its mission of developing and commercializing novel transformative pharmaceutical therapies for patients.United States$6.8M
Series A
5 startups · $112M raised
Third Arc BioThird Arc Bio is a clinical-stage biotechnology company based in Philadelphia, Pennsylvania, founded in 2022.United States$52M- EElpiscienceChina$35M
- DKDeyun KangruiDeyun Kangrui is a bio-medical high-tech enterprise that integrates R&D and the production of full-chain single-cell multi-omics technology.-$13M
UniXell BiotechnologyUniXell Biotechnology is a new-generation cell therapy drug developer, focuses on the development of a new generation of cell therapy drugs.China$7.2M
- HTHopson TechnologyHopson Technology is a natural product synthesis technology developer.China$4.1M
How this map is made. Every startup here works in Biotech and has raised money in a round we track that names Hill House Capital as an investor. Each sits under the stage of its latest round. Rebuilt nightly; updated 15 November 2026.
More portfolio maps
All portfoliosSector portfolioHill House Capital's AI portfolio15 startups · $7.7BPortfolio mapHill House Capital portfolio map107 startups · $36BCo-investorsWho invests with Hill House Capital85 co-investorsInvestments abroadHill House Capital's investments in China59 startups · $14BInvestments abroadHill House Capital's investments in the United States18 startups · $5.1BSector portfolioY Combinator's AI portfolio1,143 startups · $44B
Raising from investors like Hill House Capital?
Find the investors who back startups like yours, with their cheques, rounds and partners, in the app with filters, lists and exports.